Novel Technology for the Analysis of Gene Expression

描述：(申请人提供) 该项目的目标是开发一种用于快速 癌症相关蛋白的筛选和分析。AmberGen已经做出了 在第一阶段取得了重大进展，开发了快速 蛋白质的分离、检测和分析。称为Pro-Screen (蛋白质筛选)，这项技术是基于使用tRNA来 将特殊的标记和连接子加入到蛋白质中，这些蛋白质在 从病人的基因组DNA或信使核糖核酸中分离出来。具体成就包括 演示快速检测截断、点突变的能力 和功能缺陷。在第二阶段，AmberGen将转移重点 走向临床应用。高灵敏、快速、非同位素 将介绍基于以下内容的链截断突变检测方法 荧光-PAGE和化学发光。点突变的快速筛查 将使用UV-MALDI质谱仪进行分析。各种快速的 将开发癌症相关蛋白的功能分析，其基础是 多标记物体外掺入的研究。临床应用有待进一步完善 评估包括检测家族性腺瘤中的APC突变 息肉病(FAP)；APC和P53突变的筛查 结直肠癌的无创性诊断方法及P53蛋白的表达 肺和乳腺实体肿瘤的突变。 建议的商业应用： AmberGen将把Pro-Screen技术商业化，并在该领域进行具体应用 药物基因组学、遗传病筛查、癌症早期检测 以及用于临床诊断的肿瘤简档。商业化的早期焦点将是 引入筛查技术以检测APC和P53突变作为 非侵袭性结直肠癌检测以及BRCA筛查。随后，几个 癌症相关基因将使用AmberGen的Pro-Screen技术进行筛查。

DESCRIPTION: (provided by applicant) The goal of this project is to develop a new technology for the rapid screening and analysis of cancer-linked proteins. AmberGen has made significant progress during Phase I by developing methods for the rapid isolation, detection and analysis of proteins. Referred to as Pro-Screen (protein screening), the technology is based on the use of tRNAs to incorporate special markers and linkers into proteins which are expressed in vitro from a patient's genomic DNA or mRNA. Specific accomplishments include demonstration of the ability to rapidly detect truncations, point mutations and functional defects. During Phase II, AmberGen will shift its focus towards clinical applications. Highly sensitive, rapid and non-isotopic methods will be introduced for detecting chain-truncating mutations based on fluorescent-PAGE and chemiluminescence. Rapid screening of point mutations will be facilitated using UV -MALDI mass spectrometry. A variety of rapid functional assays of cancer-linked proteins will be developed which are based on in vitro incorporation of multiple markers. Clinical applications to be evaluated include the detection of APC mutations in familial adenamatous polyposis (FAP); the screening of APC and p53 mutations as part of a non-invasive diagnostic assay for colorectal cancer and the profiling of p53 mutations in lung and breast solid-tumors. PROPOSED COMMERCIAL APPLICATION: AmberGen will commercialize Pro-Screen technology with specific applications in the area of pharmaceutical genomics, screening of inherited diseases, early detection of cancers and profiling of tumors for clinical diagnosis. An early focus of commercialization will be the introduction of screening technology to detect APC and p53 mutations as part of a non-invasive colorectal cancer test as well as BRCA screening. Subsequently, several cancer related genes would be screened using AmberGen's Pro-Screen technology.